Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

Saved in:

Bibliographic Details
Published in:	J Gastrointest Oncol
Main Authors:	Schlintl, Verena, Huemer, Florian, Greil, Richard, Weiss, Lukas
Format:	Artigo
Language:	Inglês
Published:	AME Publishing Company 2021
Subjects:	Letter to the Editor
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC8107630/ https://ncbi.nlm.nih.gov/pubmed/34012679 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo-20-230
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items